07/30/14, Research and Development Aflibercept Solution for Injection into the Eye Receives FDA Approval for the Treatment of Diabetic Macular Edema (DME) DME is the third approved indication for aflibercept solution for injection in the U.S. more
07/18/14, Research and Development Two-Year Results From Phase 3 Trial Show Sustained Improvement in Vision for People with Diabetic Macular Edema more
|Research expenses 2013||EUR 1,654 million|
|In percent of division sales 2013
|Employees in Research & Development||7,800
(as of Dec 31, 2013)
|Main research sites||Berlin and Wuppertal, Germany and Berkeley, USA|
We hold a leading position in many therapeutic fields: for instance in the treatment of hemophilia and multiple sclerosis, in contrast media and oral contraception. We are also striving for such a leading position in oncology.
Until sufficient results are available from many different trials it is just that, potential. Effectiveness of a treatment should never be at the expense of safety; the benefit of a treatment should always outweigh the harm and is fundamental to the conduct of all clinical trials.